<DOC>
	<DOCNO>NCT02618590</DOCNO>
	<brief_summary>This multi-center retrospective study , design access best treatment strategy non-small cell lung cancer ( NSCLC ) patient harbor EGFR mutant type first/second line EGFR-TKI failure . The study end point Progression Free Survival 2 ( PFS2 ) , defined time period Progression Disease 1 ( PD1 ) Progression Disease 2 ( PD2 ) . PD1 define first tumor progression time take EGFR-TKI evaluate Recist 1.1 criterion , PD2 second tumor progression time EGFR-TKI failure matter second/third line treatment , PD2 also evaluate Recist 1.1 criterion .</brief_summary>
	<brief_title>A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients confirm stage IV ( accord International Association Study Lung Cancer（IASLC） TNM staging , 2009 ) nonsmall cell lung cancer ( NSCLC ) histology cytology year 2009 2013 , harbor EGFR mutant type ( 19 and/or 21 exon mutation ) . Appraisable disease , must least one lesion long diameter &gt; 10mm accord Recist 1.1 criterion ( contrast CT ) . Patients take EGFRTKI first/second line therapy . Patients take EGFRTKI . Patients take EGFRTKI third line . Patients take EGFRTKI concurrent chemotherapy antitumor drug . The evaluated lesion treat radiotherapy concurrent EGFRTKI . Patients whose EGFR expression positive immunochemical and/or EGFR amplification positive Fluorescence In Situ Hybridization ( FISH ) , without mutation detection evidence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>EGFR mutant type</keyword>
	<keyword>first/second line EGFR-TKI</keyword>
</DOC>